Hello everyone,
I’m Ben, the new editor for SEQanswers. I’m very excited to a part of this community and to continue the great work that was started by Eric C. Olivares (ECO).
I’m committed to making this a supportive environment where we can learn, share information, problem solve, and collaborate. I look forward to interacting with you all around the community and developing resources to help with your needs.
Here are a few things about me. I have worked in and out of different molecular biology labs for the last 9 years. In my master’s program I studied protein functions and post-translation modifications. After graduation, I started working in the exciting field of next-generation sequencing and haven’t stopped. I’ve previously worked with the MiSeq, NextSeq, NovaSeq, and the MinION, although I’m interested in all types of sequencers.
When I’m not reading and writing about sequencing technologies and bioinformatics, I’m traveling with my wife, taking Spanish lessons, learning the ukulele, and spending time with my two cats.
Take care and happy sequencing!
Ben
P.S. If you have any questions or comments, please send me a direct message here.
-
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...07-31-2026, 11:01 AM